NASDAQ:LGVN

Longeveron Competitors

$6.81
+0.03 (+0.44 %)
(As of 04/9/2021 12:00 AM ET)
Add
Compare
Today's Range
$6.55
Now: $6.81
$6.92
50-Day Range
$5.66
MA: $6.99
$8.45
52-Week Range
$5.61
Now: $6.81
$12.48
Volume195,199 shs
Average Volume795,338 shs
Market Capitalization$127.39 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Competitors

Longeveron (NASDAQ:LGVN) Vs. TERN, ANGN, SNSE, NEXI, LABP, and PRTG

Should you be buying LGVN stock or one of its competitors? Companies in the industry of "biotechnology" are considered alternatives and competitors to Longeveron, including Terns Pharmaceuticals (TERN), Angion Biomedica (ANGN), Sensei Biotherapeutics (SNSE), NexImmune (NEXI), Landos Biopharma (LABP), and Portage Biotech (PRTG).

Longeveron (NASDAQ:LGVN) and Terns Pharmaceuticals (NASDAQ:TERN) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, valuation, risk, earnings and dividends.

Valuation & Earnings

This table compares Longeveron and Terns Pharmaceuticals' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
LongeveronN/AN/AN/AN/AN/A
Terns PharmaceuticalsN/AN/AN/AN/AN/A

Profitability

This table compares Longeveron and Terns Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
LongeveronN/AN/AN/A
Terns PharmaceuticalsN/AN/AN/A

Analyst Ratings

This is a breakdown of recent ratings and price targets for Longeveron and Terns Pharmaceuticals, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Longeveron0000N/A
Terns Pharmaceuticals00303.00

Terns Pharmaceuticals has a consensus target price of $30.50, indicating a potential upside of 61.12%. Given Terns Pharmaceuticals' higher possible upside, analysts clearly believe Terns Pharmaceuticals is more favorable than Longeveron.

Summary

Terns Pharmaceuticals beats Longeveron on 2 of the 2 factors compared between the two stocks.

Longeveron (NASDAQ:LGVN) and Angion Biomedica (NASDAQ:ANGN) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, valuation, risk, earnings and dividends.

Valuation & Earnings

This table compares Longeveron and Angion Biomedica's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
LongeveronN/AN/AN/AN/AN/A
Angion BiomedicaN/AN/AN/AN/AN/A

Profitability

This table compares Longeveron and Angion Biomedica's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
LongeveronN/AN/AN/A
Angion BiomedicaN/AN/AN/A

Analyst Ratings

This is a breakdown of recent ratings and price targets for Longeveron and Angion Biomedica, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Longeveron0000N/A
Angion Biomedica00403.00

Angion Biomedica has a consensus target price of $59.3333, indicating a potential upside of 283.29%. Given Angion Biomedica's higher possible upside, analysts clearly believe Angion Biomedica is more favorable than Longeveron.

Summary

Angion Biomedica beats Longeveron on 2 of the 2 factors compared between the two stocks.

Longeveron (NASDAQ:LGVN) and Sensei Biotherapeutics (NASDAQ:SNSE) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, valuation, risk, earnings and dividends.

Valuation & Earnings

This table compares Longeveron and Sensei Biotherapeutics' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
LongeveronN/AN/AN/AN/AN/A
Sensei BiotherapeuticsN/AN/AN/AN/AN/A

Profitability

This table compares Longeveron and Sensei Biotherapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
LongeveronN/AN/AN/A
Sensei BiotherapeuticsN/AN/AN/A

Analyst Ratings

This is a breakdown of recent ratings and price targets for Longeveron and Sensei Biotherapeutics, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Longeveron0000N/A
Sensei Biotherapeutics00403.00

Sensei Biotherapeutics has a consensus target price of $29.50, indicating a potential upside of 108.78%. Given Sensei Biotherapeutics' higher possible upside, analysts clearly believe Sensei Biotherapeutics is more favorable than Longeveron.

Summary

Sensei Biotherapeutics beats Longeveron on 2 of the 2 factors compared between the two stocks.

Longeveron (NASDAQ:LGVN) and NexImmune (NASDAQ:NEXI) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, valuation, risk, earnings and dividends.

Valuation & Earnings

This table compares Longeveron and NexImmune's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
LongeveronN/AN/AN/AN/AN/A
NexImmuneN/AN/AN/AN/AN/A

Profitability

This table compares Longeveron and NexImmune's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
LongeveronN/AN/AN/A
NexImmuneN/AN/AN/A

Analyst Ratings

This is a breakdown of recent ratings and price targets for Longeveron and NexImmune, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Longeveron0000N/A
NexImmune00303.00

NexImmune has a consensus target price of $33.3333, indicating a potential upside of 86.74%. Given NexImmune's higher possible upside, analysts clearly believe NexImmune is more favorable than Longeveron.

Summary

NexImmune beats Longeveron on 2 of the 2 factors compared between the two stocks.

Longeveron (NASDAQ:LGVN) and Landos Biopharma (NASDAQ:LABP) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, valuation, risk, earnings and dividends.

Valuation & Earnings

This table compares Longeveron and Landos Biopharma's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
LongeveronN/AN/AN/AN/AN/A
Landos BiopharmaN/AN/AN/AN/AN/A

Profitability

This table compares Longeveron and Landos Biopharma's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
LongeveronN/AN/AN/A
Landos BiopharmaN/AN/AN/A

Analyst Ratings

This is a breakdown of recent ratings and price targets for Longeveron and Landos Biopharma, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Longeveron0000N/A
Landos Biopharma01302.75

Landos Biopharma has a consensus target price of $25.50, indicating a potential upside of 156.80%. Given Landos Biopharma's higher possible upside, analysts clearly believe Landos Biopharma is more favorable than Longeveron.

Summary

Landos Biopharma beats Longeveron on 2 of the 2 factors compared between the two stocks.

Longeveron (NASDAQ:LGVN) and Portage Biotech (NASDAQ:PRTG) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, valuation, risk, earnings and dividends.

Profitability

This table compares Longeveron and Portage Biotech's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
LongeveronN/AN/AN/A
Portage BiotechN/AN/AN/A

Valuation & Earnings

This table compares Longeveron and Portage Biotech's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
LongeveronN/AN/AN/AN/AN/A
Portage BiotechN/AN/AN/AN/AN/A

Analyst Ratings

This is a breakdown of recent ratings and price targets for Longeveron and Portage Biotech, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Longeveron0000N/A
Portage Biotech0000N/A


Longeveron Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Terns Pharmaceuticals logo
TERN
Terns Pharmaceuticals
2.0$18.93+2.9%$475.62 millionN/A0.00News Coverage
Gap Up
Angion Biomedica logo
ANGN
Angion Biomedica
1.7$15.48+1.4%$456.41 millionN/A0.00Gap Down
Sensei Biotherapeutics logo
SNSE
Sensei Biotherapeutics
2.0$14.13+4.7%$432.21 millionN/A0.00Gap Down
NexImmune logo
NEXI
NexImmune
2.0$17.85+2.4%$406.23 millionN/A0.00Gap Down
Landos Biopharma logo
LABP
Landos Biopharma
1.8$9.93+2.3%$398.37 millionN/A0.00Analyst Revision
PRTG
Portage Biotech
0.0$29.23+2.0%$353.19 millionN/A0.00News Coverage
Gap Down
Unity Biotechnology logo
UBX
Unity Biotechnology
1.1$5.83+1.0%$318.90 millionN/A-3.10
Kaleido Biosciences logo
KLDO
Kaleido Biosciences
1.8$7.07+6.2%$300.24 millionN/A-2.79Gap Down
LBPH
Longboard Pharmaceuticals
1.9$16.00+0.0%$270.67 millionN/A0.00Analyst Report
Analyst Revision
News Coverage
Decibel Therapeutics logo
DBTX
Decibel Therapeutics
2.2$10.54+0.8%$262.47 millionN/A0.00News Coverage
IPA
ImmunoPrecise Antibodies
0.0$12.28+5.1%$234.78 millionN/A0.00News Coverage
Annovis Bio logo
ANVS
Annovis Bio
0.0$26.54+0.1%$184.37 millionN/A0.00
GANX
Gain Therapeutics
0.0$13.98+0.1%$158.41 millionN/A0.00News Coverage
Gap Down
VINC
Vincerx Pharma
1.0$19.06+0.9%$156.39 millionN/A0.00Gap Down
EVAX
Evaxion Biotech A/S
1.7$6.09+9.2%$116.92 millionN/A0.00High Trading Volume
Analyst Revision
News Coverage
Gap Up
UPC
Universe Pharmaceuticals
0.0$4.64+3.2%$100.92 millionN/A0.00
VRDN
Viridian Therapeutics
1.7$15.66+6.7%$61.20 millionN/A0.00Gap Down
Inhibikase Therapeutics logo
IKT
Inhibikase Therapeutics
0.0$5.62+0.4%$56.49 millionN/A0.00
VIRI
Virios Therapeutics
1.3$6.17+2.3%$51.40 millionN/A0.00Gap Down
NLS Pharmaceutics logo
NLSP
NLS Pharmaceutics
1.7$3.87+1.0%$45.59 millionN/A0.00Gap Down
VLON
Vallon Pharmaceuticals
0.3$4.66+1.3%$31.74 millionN/A0.00
VRPX
Virpax Pharmaceuticals
0.3$4.86+23.5%$24.03 millionN/A0.00News Coverage
CMMB
Chemomab Therapeutics
0.0$45.90+19.8%$21.30 millionN/A0.00High Trading Volume
News Coverage
Gap Down
VYNT
Vyant Bio
0.0$4.02+4.0%$16.42 millionN/A0.00Gap Down
BCTX
BriaCell Therapeutics
0.0$5.21+15.9%$4.02 millionN/A0.00High Trading Volume
Gap Up
ACHL
Achilles Therapeutics plc American Depositary Shares
0.0$13.78+5.3%$0.00N/A0.00Gap Down
ADiTx Therapeutics logo
ADTX
ADiTx Therapeutics
1.0$2.94+0.7%$0.00N/A0.00
Apotheca Biosciences logo
CBDC
Apotheca Biosciences
0.4$0.08+0.0%$0.00N/A0.00
Avid Bioservices logo
CDMOP
Avid Bioservices
0.3$25.06+0.0%$0.00N/A0.00
RPHM
Reneo Pharmaceuticals
0.0$13.89+8.0%$0.00N/A0.00High Trading Volume
Gap Down
SCPS
Scopus BioPharma
1.4$7.57+6.2%$0.00N/A0.00Gap Down
VECT
VectivBio
0.0$24.23+29.8%$0.00N/A0.00High Trading Volume
News Coverage
Gap Up
This page was last updated on 4/11/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.